← All trials
NCT06140836
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 15, 2024
- Primary completion
- Feb 26, 2029
- Completion date
- Jan 27, 2031
- First posted
- Nov 20, 2023
- Last posted
- Dec 26, 2023
- Enrollment
- 230
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Bristol-Myers SquibbLead sponsor
- Zai Lab Pty. Ltd.Collaborator
- Bristol-Myers SquibbOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.